Jared Holz on China Drug Restrictions and Big Pharma's Investment Challenges

Potential China Drug Restrictions

• 💡 An executive order is being drafted to impose severe restrictions on drugs from China due to national security concerns.
• 📌 This comes as US pharmaceutical companies have increasingly relied on China for experimental drugs in areas like cancer, obesity, and heart disease.
• ⚠️ It's difficult to predict the immediate impact, but this is a development to monitor closely.

Impact on US Biotech and Pharma Deals

• 📊 In the first half of the year, 38% of all licensing deals involved drugs from China, seen as a way for big pharma to compensate for patent expirations.
• 🚀 Some argue that restricting Chinese drug development could benefit the US biotech sector by keeping investment dollars within the country.
• 💬 However, it's considered unlikely that the US government can completely cut off China or prevent companies from forming business ventures with Chinese entities, given the global nature of drug development.

Investment Proposition for Big Pharma

• 📉 Major pharmaceutical companies like Pfizer, Merck, and Bristol Myers are trading at low multiples and offering high dividend yields, essentially priced for zero or negative growth.
• ⚠️ These companies face challenges from both drug pricing pressures in the near term and patent expirations in the long term.
• ⏳ Investors are focused on how these companies will bridge the gap until new revenue streams emerge, with little conviction on strategic success.
• 📈 The overall sentiment is that these companies are negatively impacted on multiple fronts, making it difficult to see a clear path forward.